Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Bausch Health Companies Inc BHC


Primary Symbol: T.BHC

Healthcare
Bausch Health Companies Inc. is a global diversified pharmaceutical company. The Company develops, manufactures and markets, primarily in the therapeutic areas of gastroenterology (GI), hepatology, neurology and dermatology, and others, through Bausch + Lomb Corporation. Its Salix segment consists of sales in the United States of GI products. Its International segment consists of sales, with... see more

Recent & Breaking News (TSX:BHC)

Emerade(TM) (epinephrine 0.3 mg and 0.5 mg) now available in Canada

Canada NewsWire October 20, 2020

Bausch Health And BHVI Announce Exclusive Global Licensing Agreement For Myopia Control Contact Lens

PR Newswire October 15, 2020

Eyenovia to Host Investor Call to Discuss Recent Licensing Agreements Resulting in Total Potential License Payments and Development Cost Reimbursement and Savings of Approximately $100 Million

GlobeNewswire October 13, 2020

Bausch Health Licenses Eyenovia's Investigational Treatment For The Reduction Of Pediatric Myopia Progression In Children Ages 3-12

Canada NewsWire October 12, 2020

Salix To Present Clinical Data At United European Gastroenterology Week Virtual 2020

PR Newswire October 8, 2020

Bausch Health Companies Inc. Provides Preliminary Update On Third-Quarter 2020 Financial Results And Business Recovery

PR Newswire October 8, 2020

Bausch + Lomb Announces New Scientific And Clinical Analyses To Be Presented On Bausch + Lomb Infuse(TM) Silicone Hydrogel Daily Disposable Contact Lenses During The American Academy Of Optometry Annual Meeting

PR Newswire October 6, 2020

Salix Supports Liver Awareness Month With New Educational Initiatives

Canada NewsWire October 5, 2020

Nielsen's BASES Names LUMIFY® Eye Drops To 2020 U.S. BASES Top 25 Breakthrough Innovations List

Canada NewsWire October 1, 2020

FDA Approves Bausch + Lomb Alaway® Preservative Free (Ketotifen Fumarate) Ophthalmic Solution, 0.035%

Canada NewsWire September 25, 2020

Bausch + Lomb Announces Expanded Public Coverage for (Pr)VYZULTA® (Latanoprostene Bunod Ophthalmic Solution 0.024% w/w) in Canada

Canada NewsWire September 24, 2020

Bausch Health Releases Annual Corporate Social Responsibility Report

Canada NewsWire September 23, 2020

Bausch Health And Alfasigma Announce Resolution Of XIFAXAN® Intellectual Property Litigation

Canada NewsWire September 22, 2020

Bausch Health To Acquire Option To Purchase All Ophthalmology Assets Of Allegro Ophthalmics

PR Newswire September 21, 2020

Bausch Health Provides Company Update At 18th Annual Morgan Stanley Global Healthcare Conference

PR Newswire September 16, 2020

Bausch Foundation Releases Inaugural Activity Report

PR Newswire September 10, 2020

Bausch Health To Participate At The 18th Annual Morgan Stanley Global Healthcare Conference

Canada NewsWire September 9, 2020

Sol-Gel Technologies Collaboration Partner Filed First-to-File Paragraph IV Certification for Duobrii®

GlobeNewswire September 3, 2020

Now Available in Canada - Bausch Health, Canada Launches First of its Kind, Topical Antipsoriatic Agent in Almost Twenty Years

Canada NewsWire September 2, 2020

Bausch Health To Reduce Debt By $100 Million Using Cash Generated From Operations

PR Newswire August 31, 2020